Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

ics.com" target="_new">http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for NGX267 to treat symptoms of CIAS, the potential for NGX267 to treat xerostomia, that the well tolerated dose range may be effective for treating memory and cognitive disorders, and the planned timing of the initiating of clinical trials in CIAS and xerostomia. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular there is no guarantee that NGX267 will successfully treat symptoms of CIAS or xerostomia, the dose range may not be effective for treating memory and cognitive disorders, that the clinical trials for CIAS and xerostomia will be conducted in the anticipated timeframe or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for NGX267. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics' annual report on Form 10-K for the year ended December 31, 2006 as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Conn. , Aug. 21, 2014  Aptuit ... West Lafayette, Indiana , has enhanced ... and characterization of small and large molecules, including ... of the Bruker maXisPlus Q-TOF mass spectrometer. ... Goldman , CEO, Aptuit, said, "The expanded large ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... Feb. 2, 2012 Venture capital (VC) funding in ... Biotechnology and Medical Device industries, increased 21% during 2011, ... that includes data from the PricewaterhouseCoopers LLP/National Venture ... Reuters .  Venture capitalists invested a total of $7.5 ...
... PARK, Calif., Feb. 2, 2012  BioParadox, Inc., a ... cardiovascular disease, today announced a strategic alliance with ... are delighted to begin working with the Fogarty ... developing creative solutions for patients with challenging problems.  ...
Cached Medicine Technology:Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 2Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 3Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 4BioParadox Announces Partnership with Fogarty Institute for Innovation 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Legal ... system created by Greg Marks has been generating a ... this month. The commotion surrounding the new product has ... investigative review. , “In recent years the ... software systems, commonly referred to as robots or ‘bots,'” ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final ... of ProIntro Vol.3, a customizable title tool for FCPX ... just by dragging ProIntro Vol.3 in their timeline" says Christina ... definite time saver and i think our users will agree" ... designed titles made with Final Cut Pro X users in ...
(Date:8/23/2014)... Teen substance abuse ranks as one of ... NC. Countless adolescents throughout North Carolina struggle with a drug ... never receive professional rehab due to a lack of information ... help. Troubled Teens Holly Springs is a helpline designed to ... teenage alcohol abusers in Wake County who are seeking ...
(Date:8/22/2014)... 2014 On Friday, Aug. 22, Liberty ... Health Sciences , hosting a ceremony in its courtyard ... government and public welfare. , The 162-member inaugural class ... (LUCOM) joined Liberty staff, faculty, and community leaders ... the new medical school. Classes began on Monday, Aug. ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... A-I ratio is not a better predictor of coronary ... total cholesterol and HDL-C, according to a study in ... instruments and guidelines for coronary heart disease (CHD) prevention ... cholesterol, or both for CHD risk assessment. But in ...
... scale, multiethnic study of its kind, researchers at UCLA ... known as cytokines as a cause of Type 2 ... biological markers that may be used to more accurately ... , Reporting in the August 15 issue of the ...
... improve their understanding of the potential increased risk of ... study conducted by researchers from The Childrens Hospital in ... New Haven, CT. , Like many radiology departments around ... exposure to children caused by increased usage of CT. ...
... Columbia University Medical Center researchers have demonstrated using ... was increased in stroke and traumatic brain injury ... rehabilitative treatment that helps these patients recover lost ... the peer-reviewed journal Neurorehabilitation and Neural Repair on ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic ... this study, Joseph Delaney MSc, Dr. James Brophy ... cases with a diagnosis of gastrointestinal bleeding and ... documented a 46-fold increase in the rate of ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2
Take Performance to a Higher Level....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
Medicine Products: